Results 11 to 20 of about 260,886 (316)

IDO1 Promotes the Progression of NSCLC by Regulating the Polarization of M2 Macrophages

International Journal of General Medicine, 2023
Xiao Chen,1,2 Jie Yao,1 Meng-Yu Zhang,1 Rui Li,1 Xiao Liu,1 Yi-Qing Qu1 1Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, People’s Republic of China; 2Department of Respiratory Medicine, Tai’an City Central
Chen X, Yao J, Zhang MY, Li R, Liu X, Qu YQ   +5 more
doaj   +1 more source

Focus on Nivolumab in NSCLC [PDF]

Frontiers in Medicine, 2016
Immunotherapy is changing the treatment of non-small cell lung cancer (NSCLC). The PD-1 inhibitor nivolumab has demonstrated meaningful results in terms of efficacy with a good safety profile. The novel approach to treating NSCLC using immunotherapy still has unsolved questions and challenging issues.
Cortinovis D. L., Canova S., Abbate M., Colonese F., Bidoli P.   +4 more
openaire   +3 more sources

Liquid Biopsy and NSCLC [PDF]

Lung Cancer Management, 2016
In the era of high-throughput molecular screening and personalized medicine, difficulty in determining whether cancer mutations are truly 'actionable' remains a gray zone in NSCLC. The most important prerequisite to perform such investigations is the tumor tissue retrieval via biopsy at diagnosis and after occurrence of resistance.
Trombetta, D., Sparaneo, A., Fabrizio, F. P., Muscarella, L. A.   +3 more
openaire   +2 more sources

PI3K Pathway in NSCLC [PDF]

Frontiers in Oncology, 2012
The phosphatidylinositol 3-kinases (PI3Ks) are members of a family of intracellular lipid kinases that phosphorylate the 3'-hydroxyl group of phosphatidylinositol and phosphoinositides. PI3K regulate signaling pathways for neoplasia, including cell proliferation, adhesion, survival, and motility.
Martinez-Martí, Alex, Felip, Enriqueta
openaire   +3 more sources

Precision Surgery in NSCLC

Cancers, 2023
Non-small cell lung cancer (NSCLC) is still one of the leading causes of death worldwide. This is mostly because the majority of lung cancers are discovered in advanced stages. In the era of conventional chemotherapy, the prognosis of advanced NSCLC was grim. Important results have been reported in thoracic oncology since the discovery of new molecular
Cannone, Giorgio, Comacchio, Giovanni Maria, Pasello, Giulia, Faccioli, Eleonora, Schiavon, Marco, Dell'Amore, Andrea, Mammana, Marco, Rea, Federico   +7 more
openaire   +3 more sources

Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): A feasibility study [PDF]

, 2006
Background: Concurrent chemoradiotherapy has improved survival in inoperable stage III non-small cell lung cancer (NSCLC). This phase I trial was performed in order to establish a dose recommendation for oral vinorelbine in combination with cisplatin and
Schmidt, Michael, Aubert, Delphine, Flentje, Michael, Semrau, Sabine, Fietkau, Rainer, Fittipaldo, Alberto, Huber, Rudolf M., Kleine, Philip, Beckmann, Gabriele   +8 more
core   +1 more source

The efficacy of durvalumab in locally advanced lung carcinoma [PDF]

Archive of Oncology
Background: The integration of durvalumab, an immune checkpoint inhibitor, as consolidation therapy following platinum-based chemoradiotherapy has redefined the standard of care for patients with stage III, unresectable non-small cell lung cancer (NSCLC)
Knežević Isidora, Raškov Stefan, Ðorđević Milica, Zarić Bojan   +3 more
doaj   +1 more source

Angiogenesis Inhibitors in NSCLC [PDF]

International Journal of Molecular Sciences, 2017
Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with advanced NSCLC in combination with chemotherapy ...
Manzo, Anna, Montanino, Agnese, Carillio, Guido, Costanzo, Raffaele, Sandomenico, Claudia, Normanno, Nicola, Piccirillo, Maria Carmela, Daniele, Gennaro, Perrone, Francesco, Rocco, Gaetano, Morabito, Alessandro   +10 more
openaire   +2 more sources

Immunotherapeutic Advances for NSCLC

Biologics: Targets and Therapy, 2021
Immunotherapy with antibodies against PD-1 or PD-L1, either alone or in combination with chemotherapy, has revolutionized treatment paradigms of non-small cell lung cancer (NSCLC) patients without oncogenic driver alterations. These agents, namely immune checkpoint inhibitors (ICIs), have also widely demonstrated a remarkable efficacy in locally ...
Massafra, Marco, Passalacqua, Maria Ilenia, Gebbia, Vittorio, Macrì, Paolo, Lazzari, Chiara, Gregorc, Vanesa, Buda, Carmelo, Altavilla, Giuseppe, Santarpia, Mariacarmela   +8 more
openaire   +5 more sources

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group [PDF]

, 2005
Purpose: This phase III randomized trial compared two chemotherapy regimens, gemcitabine plus carboplatin and mitomycin, ifosfamide, and cisplatin, in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC).
Harper, P.G., Johnson, P.W.M., Harper, P. G., Qian, W., Rudd, R. M., Spiro, S.G., Gregory, W. M., Hatton, M., Eisen, T. G., James, L.E., Rankin, E. M., Johnson, P. W. M., Rankin, E.M., Spiro, S. G., Rudd, R.M., Lee, S. M., Littler, J. A. H., Lee, S.M., Littler, J.A.H., Eisen, T.G., Martin, W.M.C., Gregory, W.M., James, L. E., Gower, N. H., Martin, W. M. C., Gower, N.H.   +25 more
core   +1 more source